Retinal manifestations of oncologic and hematologic conditions

International Ophthalmology Clinics

Volumn 52, Issue 1, 2012, Pages 67-91

  Lin, Phoebe ^a   Mruthyunjaya, Prithvi ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE;

BONE MARROW DISEASE; CANCER ASSOCIATED RETINOPATHY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHOROIDAL METASTASIS; CORTICOSTEROID THERAPY; DIFFUSE UVEAL MELANOCYTIC PROLIFERATION; DISSEMINATED INTRAVASCULAR CLOTTING; EXTERNAL BEAM RADIOTHERAPY; HEMATOLOGIC MALIGNANCY; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MELANOMA ASSOCIATED RETINOPATHY; METASTASIS; NEOPLASTIC AUTOIMMUNE RETINOPATHY; PARANEOPLASTIC SYNDROME; PLASMAPHERESIS; PRIMARY CHOROIDAL LYMPHOMA; PRIMARY TUMOR; PRIMARY VITREORETINAL LYMPHOMA; PRIORITY JOURNAL; RETINA DISEASE; RETINOPATHY; REVIEW; SOLID TUMOR; VITREORETINAL METASTASIS;

HEMATOLOGIC DISEASES; HUMANS; NEOPLASMS; PARANEOPLASTIC SYNDROMES, OCULAR;

EID: 82455179510     PISSN: 00208167     EISSN: 15369617     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31823bbd14     Document Type: Review

References (137)

1. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol. 1983;101:564-569. (Pubitemid 13116463)
2. Klingele TG, Burde RM, Rappazzo JA, et al. Paraneoplastic retinopathy. J Clin Neuroophthalmol. 1984;4:239-245. (Pubitemid 15004362)
3. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol. 2003;48:12-38. (Pubitemid 36138821)
4. Sawyer RA, Selhorst JB, Zimmerman LE, et al. Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol. 1976;81:606-613.
5. Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127-134.
6. Khan N, Huang JJ, Foster CS. Cancer associated retinopathy (CAR): an autoimmunemediated paraneoplastic syndrome. Semin Ophthalmol. 2006;21:135-141. (Pubitemid 44266787)
7. Thirkill CE, Keltner JL, Tyler NK, et al. Antibody reactions with retina and cancerassociated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol. 1993;111:931-937. (Pubitemid 23208799)
8. Matus G, Dicato M, Focan C. (Cancer associated retinopathy (CAR). Two clinical cases and review of the literature). Rev Med Liege. 2007;62:166-169. (Pubitemid 351448346)
9. Raghunath A, Adamus G, Bodurka DC, et al. Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube. J Neuroophthalmol. 2010;30:252-254.
10. Pepple KL, Cusick M, Jaffe GJ, et al. SD-OCTand Autofluorescence Characteristics of Autoimmune Retinopathy,'' ARVO Meeting Abstracts April 22, 2011 52:4284.
11. Buchanan TA, Gardiner TA, Archer DB. An ultrastructural study of retinal photoreceptor degeneration associated with bronchial carcinoma. Am J Ophthalmol. 1984; 97:277-287. (Pubitemid 14160538)
12. Thirkill CE, Tait RC, Tyler NK, et al. The cancer-associated retinopathy antige is a recoverin-like protein. Invest Ophthalmol Vis Sci. 1992;33:2768-2772.
13. Polans AS, Witkowska D, Haley TL, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci U S A. 1995;92:9176-9180.
14. Adamus G, Machnicki M, Elerding H, et al. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun. 1998;11:523-533. (Pubitemid 28520211)
15. Adamus G, Machnicki M, Seigel GM. Apoptotic retinal cell death induced by antirecoverin autoantibodies of cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1997;38:283-291. (Pubitemid 27085684)
16. Adamus G, Aptsiauri N, Guy J, et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol. 1996;78: 120-129. (Pubitemid 26084591)
17. Weleber RG, Watzke RC, Shults WT, et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol. 2005;139:780-794. (Pubitemid 40614762)
18. Eichen JG, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol. 2001; 21:168-172. (Pubitemid 33028978)
19. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240: 889-895.
20. Hollemann T, Bellefroid E, Pieler T. The Xenopus homologue of the Drosophila gene tailless has a function in early eye development. Development. 1998;125:2425-2432. (Pubitemid 28362402)
21. Kikuchi T, Arai J, Shibuki H, et al. Tubby-like protein 1as an autoantigen in cancerassociated retinopathy. J Neuroimmunol. 2000;103:26-33. (Pubitemid 30058250)
22. Kornguth SE, Kalinke T, Grunwald GB, et al. Anti-neurofilament antibodies in the sera of patients with small cell carcinoma of the lung and with visual paraneoplastic syndrome. Cancer Res. 1986;46:2588-2595. (Pubitemid 16120736)
23. OhguroH, Ogawa K, Nakagawa T. Recoverin and Hsc 70 are found as autoantigens in patients with cancer-associated retinopathy. Invest Ophthalmol Vis Sci. 1999;40:82-89. (Pubitemid 29029575)
24. Potter MJ, Adamus G, Szabo SM, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol. 2002;134:128-130. (Pubitemid 34722726)
25. Keltner JL, Thirkill CE, Tyler NK, et al. Management and monitoring of cancerassociated retinopathy. Arch Ophthalmol. 1992;110:48-53.
26. Yoon YH, Cho EH, Sohn J, et al. An unusual type of cancer-associated retinopathy in a patient with ovarian cancer. Korean J Ophthalmol. 1999;13:43-48.
27. Nudelman E, Hakomori S, Kannagi R, et al. Characterization of a human melanomaassociated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem. 1982;257:12752-12756. (Pubitemid 13209991)
28. Thirkill CE, FitzGerald P, Sergott RC, et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med. 1989;321:1589-1594. (Pubitemid 20008239)
29. Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol. 1999;117:471-477. (Pubitemid 29169641)
30. Adamus G, Webb S, Shiraga S, et al. Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells. J Autoimmun. 2006;26: 146-153. (Pubitemid 43138885)
31. Ohguro H, Ogawa K, Maeda T, et al. Retinal dysfunction in cancer-associated retinopathy is improved by Ca(2+) antagonist administration and dark adaptation. Invest Ophthalmol Vis Sci. 2001;42:2589-2595. (Pubitemid 32954868)
32. Espandar L, O'Brien S, Thirkill C, et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol. 2007;83:295-302. (Pubitemid 46952241)
33. Remulla JF, Pineda R, Gaudio AR, et al. Cutaneous melanoma-associated retinopathy with retinal periphlebitis. Arch Ophthalmol. 1995;113:854-855.
34. Rougier MB, Hostyn P, Bret-Dibat C, et al. Paraneoplastic retinopathy associated with cutaneous melanoma. An update apropos of a case. J Fr Ophtalmol. 1995;18:396-403.
35. Chan C, O'Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Exp Ophthalmol. 2001;29:235-238. (Pubitemid 32791438)
36. Gittinger JW Jr., Smith TW. Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol. 1999;127:612-614. (Pubitemid 29215780)
37. Potter MJ, Thirkill CE, Dam OM, et al. Clinical and immunocytochemical findings in a case of melanoma-associated retinopathy. Ophthalmology. 1999;106:2121-2125. (Pubitemid 30194234)
38. Lei B, Bush RA, Milam AH, et al. Human melanoma-associated retinopathy (MAR) antibodies alter the retinal ON-response of the monkey ERG in vivo. Invest Ophthalmol Vis Sci. 2000;41:262-266. (Pubitemid 30036576)
39. Dhingra A, Fina ME, Neinstein A, et al. Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. J Neurosci. 2011;31:3962-3967.
40. Keltner JL, Thirkill CE. The 22-kDa antigen in optic nerve and retinal diseases. J Neuroophthalmol. 1999;19:71-83. (Pubitemid 30250053)
41. Pfohler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy. Int J Cancer. 2007;120:788-795. (Pubitemid 46175398)
42. Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol. 2009;127:1572-1580.
43. John GB, Shang Y, Li L, et al. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell. 2005;16:1543-1554. (Pubitemid 40349586)
44. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol. 2001;21:173-187. (Pubitemid 33028979)
45. Boeck K, Hofmann S, Klopfer M, et al. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol. 1997;137: 457-460. (Pubitemid 27421581)
46. Jacobzone C, Cochard-Marianowski C, Kupfer I, et al. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol. 2004;140:1258-1261. (Pubitemid 39362245)
47. Handler MZ, Mruthyunjaya P, Nelson K. Melanoma-associated retinopathy: a presenting sign of metastatic disease. J Am Acad Dermatol. 2011;65:e9-e11.
48. Subhadra C, Dudek AZ, Rath PP, et al. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol. 2008;28:23-26. (Pubitemid 351416887)
49. Powell SF, Dudek AZ. Treatment of melanoma-associated retinopathy. Curr Treat Options Neurol. 2010;12:54-63.
50. Barr CC, Zimmerman LE, Curtin VT, et al. Bilateral diffuse melanocytic uveal tumors associated with systemic malignant neoplasms: a recently recognized syndrome. Arch Ophthalmol. 1982;100:249-255. (Pubitemid 12162230)
51. Gass JD, Gieser RG, Wilkinson CP, et al. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol. 1990;108:527-533. (Pubitemid 20142534)
52. Prusiner PE, Butler A, Yavitz EQ, et al. Metastatic adenocarcinoma presenting as bilateral blindness. Ann Ophthalmol. 1983;15:653-656. (Pubitemid 13076773)
53. Ryll DL, Campbell RJ, Robertson DM, et al. 7. Pseudometastatic lesions of the choroid. Ophthalmology. 1980;87:1181-1186.
54. Machemer R. (On the pathogenesis of the flat malignant melanoma). Klin Monbl Augenheilkd. 1966;148:641-652.
55. O'Neal KD, Butnor KJ, Perkinson KR, et al. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol. 2003;48:613-625. (Pubitemid 37386278)
56. Filipic M, Ambler JS. Bilateral diffuse melanocytic uveal tumours associated with systemic malignant neoplasm. Aust N Z J Ophthalmol. 1986;14:293-299.
57. Besirli CG, Comer GM, High-resolution OCT. imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging. 2010;41:(Suppl):S96-S100.
58. Ritland JS, Eide N, Tausjo J. Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report. Acta Ophthalmol Scand. 2000;78:366-368. (Pubitemid 30333316)
59. Eliassi-Rad B, Albert DM, Green WR. Frequency of ocular metastases in patients dying of cancer in eye bank populations. Br J Ophthalmol. 1996;80:125-128. (Pubitemid 26058544)
60. Bloch RS, Gartner S. The incidence of ocular metastatic carcinoma. Arch Ophthalmol. 1971;85:673-675.
61. Nelson CC, Hertzberg BS, Klintworth GK. A histopathologic study of 716 unselected eyes in patients with cancer at the time of death. Am J Ophthalmol. 1983;95:788-793.
62. Pelzek CD, Schachat AP. Retina l metastases. In: Schachat AP, ed. Retina volume 1. 4th ed, St Louis: Mosby; 2006:641-650.
63. Best SJ, Taylor W, Allen JP. Metastatic cutaneous malignant melanoma of the vitreous and retina. Aust N Z J Ophthalmol. 1990;18:397-400.
64. Flindall RJ, Fleming KO. Metastatic tumour of the retina. Can J Ophthalmol. 1967;2:130-132.
65. Kennedy RJ, Rummel WD, Mc CJ, et al. Metastatic carcinoma of the retina; report of a case and the pathologic findings. AMA Arch Ophthalmol. 1958;60:12-18.
66. Klein R, Nicholson DH, Luxenberg MN. Retinal metastasis from squamous cell carcinoma of the lung. Am J Ophthalmol. 1977;83:358-361. (Pubitemid 8063265)
67. Koenig RP, Johnson DL, Monahan RH. Bronchogenic carcinoma with metastases to the retina. Am J Ophthalmol. 1963;56:827-829.
68. Leys AM, Van Eyck LM, Nuttin BJ, et al. Metastatic carcinoma to the retina. Clinicopathologic findings in two cases Arch Ophthalmol. 1990;108:1448-1452. (Pubitemid 20344702)
69. Liddicoat DA, Wolter JR, Wilkinson WC. Retinal metastasis of malignant melanoblastoma: a case report. Am J Ophthalmol. 1959;48:172-177.
70. Riffenburgh RS. Metastatic malignant melanoma to the retina. Arch Ophthalmol. 1961;66:487-489.
71. Spraul CW, Martin DF, Hagler WS, et al. Cytology of metastatic cutaneous melanoma to the vitreous and retina. Retina. 1996;16:328-332. (Pubitemid 26282716)
72. Takagi T, Yamaguchi T, Mizoguchi T, et al. A case of metastatic optic nerve head and retinal carcinoma with vitreous seeds. Ophthalmologica. 1989;199:123-126. (Pubitemid 19226853)
73. Young SE, Cruciger M, Lukeman J. Metastatic carcinoma to the retina: case report. Ophthalmology. 1979;86:1350-1354.
74. Kim CY, Ha CW, Lee SC. Vitreous and retinal metastasis from gastric cancer. Eur J Ophthalmol. 2010;20:615-617.
75. Soheilian M, Mirbabai F, Shahsavari M, et al. Metastatic cutaneous melanoma to the vitreous cavity masquerading as intermediate uveitis. Eur J Ophthalmol. 2002;12:324-327.
76. Zaldivar RA, Michels M, Grant KF, et al. Metastatic breast carcinoma to the vitreous. Retina. 2004;24:226-230. (Pubitemid 38509608)
77. Char DH, Schwartz A, Miller TR, et al. Ocular metastases from systemic melanoma. Am J Ophthalmol. 1980;90:702-707. (Pubitemid 11250563)
78. Robertson DM, Wilkinson CP, Murray JL, et al. Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy. Ophthalmology. 1981;88:1296-1301. (Pubitemid 12251179)
79. Duke JR, Walsh FB. Metastatic carcinoma to the retina. Am J Ophthalmol. 1959;47: (1 Part 1):44-48.
80. Wharam MD, Schachat AP. Choroidal metastasis. In: Schachat AP, ed. Retina volume 1. 4th ed, St. Louis: Mosby; 2006:812.
81. Stephens RF, Shields JA. Diagnosis and management of cancer metastatic to the uvea: a study of 70 cases. Ophthalmology. 1979;86:1336-1349.
82. Demirci H, Shields CL, Chao AN, et al. Uveal metastasis from breast cancer in 264 patients. Am J Ophthalmol. 2003;136:264-271. (Pubitemid 36904073)
83. Shields JA, Shields CL, Eagle RC Jr., et al. Lung cancer presenting as vitreous hemorrhage from choroidal metastasis. Retina. 2004;24:168-170. (Pubitemid 38240862)
84. Arevalo JF, Fernandez CF, Garcia RA. Optical coherence tomography characteristics of choroidal metastasis. Ophthalmology. 2005;112:1612-1619. (Pubitemid 41725421)
85. Torres VL, Brugnoni N, Kaiser PK, et al. Optical coherence tomography enhanced depth imaging of choroidal tumors. Am J Ophthalmol. 2011;151:586-593 e2.
86. Ishida T, Ohno-Matsui K, Kaneko Y, et al. Autofluorescence of metastatic choroidal tumor. Int Ophthalmol. 2009;29:309-313.
87. Maor M, Chan RC, Young SE. Radiotherapy of choroidal metastases: breast cancer as primary site. Cancer. 1977;40:2081-2086. (Pubitemid 8239694)
88. Rosset A, Zografos L, Coucke P, et al. Radiotherapy of choroidal metastases. Radiother Oncol. 1998;46:263-268. (Pubitemid 28157276)
89. Logani S, Gomez H, Jampol LM. Resolution of choroidal metastasis in breast cancer with high estrogen receptors. Arch Ophthalmol. 1992;110:451-452.
90. Shields CL, Shields JA, De Potter P, et al. Plaque radiotherapy for the management of uveal metastasis. Arch Ophthalmol. 1997;115:203-209. (Pubitemid 27083793)
91. Tsina EK, Lane AM, Zacks DN, et al. Treatment of metastatic tumors of the choroids with proton beam irradiation. Ophthalmology. 2005;112:337-343. (Pubitemid 40202573)
92. Allen RA, Straatsma BR. Ocular involvement in leukemia and allied disorders. Arch Ophthalmol. 1961;66:490-508.
93. Leonardy NJ, Rupani M, Dent G, et al. Analysis of 135 autopsy eyes for ocular involvement in leukemia. Am J Ophthalmol. 1990;109:436-444. (Pubitemid 20122185)
94. Schachat AP, Markowitz JA, Guyer DR, et al. Ophthalmic manifestations of leukemia. Arch Ophthalmol. 1989;107:697-700. (Pubitemid 19140999)
95. Reddy SC, Jackson N, Menon BS. Ocular involvement in leukemia-a study of 288 cases. Ophthalmologica. 2003;217:441-445. (Pubitemid 37329240)
96. Holt JM, Gordon-Smith EC. Retinal abnormalities in diseases of the blood. Br J Ophthalmol. 1969;53:145-160.
97. Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology. 1987;94:1631-1639. (Pubitemid 18006894)
98. Kim TS, Duker JS, Hedges TR III. Retinal angiopathy resembling unilateral frosted branch angiitis in a patient with relapsing acute lymphoblastic leukemia. Am J Ophthalmol. 1994;117:806-808. (Pubitemid 24172038)
99. Jackson N, Reddy SC, Harun MH, et al. Macular haemorrhage in adult acute leukaemia patients at presentation and the risk of subsequent intracranial haemorrhage. Br J Haematol. 1997;98:204-209. (Pubitemid 27348816)
100. Swartz M, Schumann GB. Acute leukemic infiltration of the vitreous diagnosed by pars plana aspiration. Am J Ophthalmol. 1980;90:326-330. (Pubitemid 10001048)
101. Mehta AB, Goldman JM, Kohner E. Hyperleucocytic retinopathy in chronic granulocytic leukaemia: the role of intensive leucapheresis. Br J Haematol. 1984; 56:661-667. (Pubitemid 14128142)
102. Merchant A, Foster CS. Primary intraocular lymphoma. Int Ophthalmol Clin. 1997;37:101-115. (Pubitemid 28016290)
103. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95:1504-1510.
104. Geier SA, Nasemann J, Klauss V, et al. Frosted branch angiitis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113:203-205.
105. Behbehani RS, Vacarezza N, Sergott RC, et al. Isolated optic nerve lymphoma diagnosed by optic nerve biopsy. Am J Ophthalmol. 2005;139:1128-1130. (Pubitemid 40813338)
106. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Experiment Ophthalmol. 2008;36:564-578.
107. Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242:901-913. (Pubitemid 39562324)
108. Singh AD, Lewis H, Schachat AP. Primary lymphoma of the central nervous system. Ophthalmol Clin North Am. 2005;18:199-207, x. (Pubitemid 40348824)
109. Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115: 1152-1156. (Pubitemid 27387951)
110. Ohguro N, Hashida N, Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol. 2008;126:1002-1003. (Pubitemid 352008390)
111. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709-1716. (Pubitemid 35012013)
112. Knapp AJ, Gartner S, Henkind P. Multiple myeloma and its ocular manifestations. Surv Ophthalmol. 1987;31:343-351. (Pubitemid 17076519)
113. Payne T, Karp LA, Zimmerman LE. Intraocular involvement in Burkitt's lymphoma. Arch Ophthalmol. 1971;85:295-298.
114. Omoti AE, Omoti CE. Ophthalmic manifestations of multiple myeloma. West Afr J Med. 2007;26:265-268. (Pubitemid 351802538)
115. Maisel JM, Miller F, Sibony PA, et al. Multiple myeloma presenting with ocular inflammation. Ann Ophthalmol. 1987;19:170-174. (Pubitemid 17088617)
116. Schur PH, Appel L. Waldenstrom's macroglobulinemia with pleural effusion. N Y State J Med. 1961;61:2431-2439.
117. Sen HN, Chan CC, Caruso RC, et al. Waldenstrom's macroglobulinemia- associated retinopathy. Ophthalmology. 2004;111:535-539.
118. Carr RE, Henkind P. Retinal findings associated with serum hyperviscosity. Am J Ophthalmol. 1963;56:23-31.
119. Jorge R, Scott IU, Oliveira RC, et al. Ocular findings in a patient with Castleman's disease before and after treatment with immunosuppression and plasmapheresis. Ophthalmic Surg Lasers Imaging. 2010;41: Online, doi: 10.3928/15428877-20100929-10.
120. Elagouz M, Jyothi S, Gupta B, et al. Sickle cell disease and the eye: old and new concepts. Surv Ophthalmol. 2010;55:359-377.
121. Horne MK 3rd. Sickle cell anemia as a rheologic disease. Am J Med. 1981;70: 288-298. (Pubitemid 11146013)
122. Babalola OE, Wambebe CO. Ocular morbidity from sickle cell disease in a Nigerian cohort. Niger Postgrad Med J. 2005;12:241-244.
123. Gagliano DA, Goldberg MF. The evolution of salmon-patch hemorrhages in sickle cell retinopathy. Arch Ophthalmol. 1989;107:1814-1815. (Pubitemid 20013147)
124. Welch RB, Goldberg MF. Sickle-cell hemoglobin and its relation to fundus abnormality. Arch Ophthalmol. 1966;75:353-362.
125. Goldberg MF. Retinal neovascularization in sickle cell retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:(3 Pt 1):OP409-OP431.
126. Farber MD, Jampol LM, Fox P, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1991; 109:363-367.
127. Fox PD, Vessey SJ, Forshaw ML, et al. Influence of genotype on the natural history of untreated proliferative sickle retinopathy-an angiographic study. Br J Ophthalmol. 1991;75:229-231.
128. Goldberg MF, Dizon R, Moses VK. Sickled erythrocytes, hyphema, and secondary glaucoma: VI. The relationship between intracameral blood cells and aqueous humor pH, PO2, and PCO2. Ophthalmic Surg. 1979;10:78-88. (Pubitemid 9200927)
129. Pulido JS, Flynn HW Jr, Clarkson JG, et al. Pars plana vitrectomy in the management of complications of proliferative sickle retinopathy. Arch Ophthalmol. 1988;106:1553-1557.
130. Hoines J, Buettner H. Ocular complications of disseminated intravascular coagulation (DIC) in abruptio placentae. Retina. 1989;9:105-109. (Pubitemid 19189240)
131. Patel N, Riordan-Eva P, Chong V. Persistent visual loss after retinochoroidal infarction in pregnancy-induced hypertension and disseminated intravascular coagulation. J Neuroophthalmol. 2005;25:128-130. (Pubitemid 40796135)
132. Ahn BY, Choi KD, Choi YJ, et al. Isolated monocular visual loss as an initial manifestation of polycythemia vera. J Neurol Sci. 2007;258:151-153.
133. Chambers JK, Salinas CF. Ocular findings in dyskeratosis congenita. Birth Defects Orig Artic Ser. 1982;18:(3B):167-174.
134. Teixeira LF, Shields CL, Marr B, et al. Bilateral retinal vasculopathy in a patient with dyskeratosis congenita. Arch Ophthalmol. 2008;126:134-135.
135. Tsilou ET, Giri N, Weinstein S, et al. Ocular and orbital manifestations of the inherited bone marrow failure syndromes: Fanconi anemia and dyskeratosis congenita. Ophthalmology. 2010;117:615-622.
136. AgarwalM, Yeh S, Faia LJ, et al. Posterior segment ophthalmic complications of aplastic anemia. Ophthalmic Surg Lasers Imaging. 2010;41: Online, doi: 10.3928/15428877- 20100625-04.
137. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240:180-196. (Pubitemid 36097054)